Related Experiment Video
Updated: Sep 17, 2026

05:19
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
Two-year outcomes following PSMA PET and MRI guided prostate SABR with simultaneous focal boost: a brief report from
Yasir Alayed1, Andrew Loblaw2, Lucas C Mendez3
1Division of Radiation Oncology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Abstract:
ARGOS-CLIMBER is a phase 1/2 trial evaluating PSMA PET and MRI guided prostate SABR with a simultaneous boost to intraprostatic and nodal disease in men with unfavourable intermediate and high-risk prostate cancer. The updated results demonstrate acceptable safety and quality of life with high biochemical and imaging response rates.
